Compare Incyte Corporation (INCY) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs State Street PDR S&P Retail ETF — how do they compare? Incyte Corporation trades at $112.8 (market cap $22.85B), while State Street PDR S&P Retail ETF trades at $86.52 (market cap $389.66M). The key difference: Incyte Corporation is far larger — about 58.6× State Street PDR S&P Retail ETF's market cap, and State Street PDR S&P Retail ETF is more actively traded (4,275,820 versus 1,927,029). Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and State Street PDR S&P Retail ETF for 44 Days on average.
| INCY | XRT | |
|---|---|---|
Market Cap | $22.85B | $389.66M |
Volume | 1,927,029 | 4,275,820 |
Sector | Health | Broad Market / Factor |
52-Week High | $129.93 | $92.35 |
52-Week Low | $83.80 | $77.28 |
Typical Hold Time | 33 Days | 44 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical outlook despite mixed moving average signals. The company shows strong fundamentals with $5.14B revenue, 27.71% net margin, and robust cash flow of $1.41B. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI position the company for growth, with analysts projecting $5.8B revenue and $1.6B net income for 2026.
The investment case centers on Incyte's successful diversification strategy and strong profitability metrics, though investors face risks from JAKAFI patent expiration in 2029 and near-term earnings volatility. With 52% analyst buy ratings and a $132.43 consensus price target representing 17% upside, the stock offers growth potential but requires monitoring of pipeline execution.
XRT (SPDR S&P Retail ETF) trades at $82.91, showing minimal daily movement with a slight decline of 0.05%. Technical indicators signal a bearish trend overall, with moving averages particularly negative. The ETF faces headwinds from higher interest rates and inflation impacting consumer spending, though recent retail sales data showed a strong August rebound. Analyst sentiment remains cautious with expectations of continued underperformance against broader market indices.
The retail sector faces macroeconomic pressures including inflation and rising rates that weigh on consumer discretionary spending. While holiday sales projections exceed $1 trillion, selective consumer behavior favors value-oriented retailers. Near-term performance depends on Fed policy direction and consumer resilience during the critical holiday season, with technical resistance at $83-$84 levels limiting upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
